Catalent Inc
NYSE:CTLT
Intrinsic Value
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer healt... [ Read More ]
The intrinsic value of one
CTLT
stock under the Base Case scenario is
57.41
USD.
Compared to the current market price of 37.18 USD,
Catalent Inc
is
Undervalued by 35%.
Valuation History
Catalent Inc
Intrinsic Value History...
Our system is conducting in-depth analyses to map out the stock's valuation journey. Thank you for waiting.
Fundamental Analysis
2024-Q1 Earnings Call
NEW
Artifical Intelligence Analysis
The quarter saw a 4%-6% decline in net revenue at $982 million due to a $85 million decrease in COVID-19 related revenue, offset by growths of 11% and 5% in Biologics and PCH respectively. Adjusted EBITDA plummeted by 38% to $115 million, and the company recorded an adjusted net loss of $19 million. Despite this, fiscal '24 guidance remains unchanged, expecting net revenue between $4.3 billion to $4.5 billion (3% growth at midpoint), adjusted EBITDA from $680 million to $760 million, and adjusted net income ranging from $113 million to $175 million.
Balance Sheet Decomposition
Catalent Inc
| Current Assets | 2.7B |
| Cash & Short-Term Investments | 252m |
| Receivables | 1.5B |
| Other Current Assets | 949m |
| Non-Current Assets | 8.1B |
| PP&E | 3.7B |
| Intangibles | 4B |
| Other Non-Current Assets | 386m |
| Current Liabilities | 1.5B |
| Accounts Payable | 394m |
| Accrued Liabilities | 279m |
| Other Current Liabilities | 814m |
| Non-Current Liabilities | 4.6B |
| Long-Term Debt | 4.3B |
| Other Non-Current Liabilities | 379m |
CTLT Profitability Score
Profitability Due Diligence
Catalent Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Catalent Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
CTLT Solvency Score
Solvency Due Diligence
Catalent Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Catalent Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTLT Price Targets Summary
Catalent Inc
According to Wall Street analysts, the average 1-year price target for
CTLT
is 49.54 USD
with a low forecast of 40.4 USD and a high forecast of 60.9 USD.
Ownership
CTLT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CTLT Price
Catalent Inc
| Average Annual Return | 42.9% |
| Standard Deviation of Annual Returns | 48.64% |
| Max Drawdown | -78% |
| Market Capitalization | 6.7B USD |
| Shares Outstanding | 180 270 000 |
| Percentage of Shares Shorted | 6.64% |
CTLT News
Last Video News
Catalent Inc
Last Important Events
Catalent Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Catalent Inc
Company Profile
Catalent Inc
Country
Industry
Market Cap
Dividend Yield
Description
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 17,300 full-time employees. The company went IPO on 2014-07-31. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.
Contact
IPO
Employees
Officers
The intrinsic value of one
CTLT
stock under the Base Case scenario is
57.41
USD.
Compared to the current market price of 37.18 USD,
Catalent Inc
is
Undervalued by 35%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
